SMARCA4 and breast cancer: Knockdown of BRG1 in breast cancer cells similarly leads to reduced proliferation rates in vitro and in situ xenografts [63, 65], while complete knockout of BRG1 via CRISPR/Cas9 technology results in cell death, confirming the requirement of BRG1 for breast cancer cell survival [63].